Company: Johnson & Johnson
2019 sales: $6.62 billion
Projected 2026 sales: $6.32 billion
Projected CAGR: -1%
Used for: plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis
Johnson & Johnson's stalwart immunology med Stelara has long held a spot in the blockbuster rankings with its uncommon mechanism of action and a small group of approved indications. Now, Stelara has expanded its range to a fourth indiction—thanks to an FDA nod late last year—and that could help it maintain its peak sales in the years to come.
Stelara, an IL-12,23 inhibitor, picked up $6.62 billion in sales in 2019, its 10th year on the market after an initial FDA approval in 2009. With a recent approval in ulcerative colitis, Stelara's sales are mostly expected to stay flat through 2026 at $6.32 billion, despite increasing competition and biosimilars in the field, according to Evaluate Pharma.
That FDA nod in ulcerative colitis, granted in October, was based on two phase 3 trials showing 19% of patients on Stelara achieved remission at eight weeks, and 45% of Stelara patients hit remission by the one-year mark.